Jwell Pharmaceuticals

Jwell Pharmaceuticals is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to developing breakthrough treatments for metabolic disorders. The company focuses on the engineering of multi-target peptide agonists, with a primary emphasis on triple agonists that simultaneously activate the GLP-1, GIP, and glucagon receptors. Its lead asset, JW-101, is currently undergoing Phase 1 clinical trials for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). By targeting multiple metabolic pathways, Jwell aims to provide superior therapeutic outcomes compared to traditional single-target therapies. The company is supported by leading investors such as Qiming Venture Partners and IDG Capital.